In west Africa, splenic lymphoma with villous lymphocytes and hyper-reactive malarial splenomegaly have many clinical and immunological features in common suggesting an aetiopathological link. We hypothesize that in hyper-reactive malarial splenomegaly the dysregulated immune response to repeated malaria infections results in a stimulated, proliferating pool of B cells in which perturbation of cell growth and apoptosis by environmental and other factors promotes the development of SLVL. In Africa these factors are likely to include infectious agents several of which have already been associated with Bcell non-Hodgkin's lymphomas.
Introduction
Many of the lymphoproliferative disorders occurring in Europe and north America have also been described from the African continent, though there is limited prevalence data available and accurate classification has been hampered by a lack of resources. One of the more recently defined and unusual types of lymphoma, splenic lymphoma with villous lymphocytes (SLVL), has been reported from Ghana, west Africa 1 in the last few years.
Splenic lymphoma with villous lymphocytes
SLVL was first described by Melo et al 2 as a B cell disorder primarily affecting elderly men. It is characterised by splenic enlargement without lymphadenopathy, a moderate lymphocytosis and a small, usually IgM, monoclonal gammopathy. 3 In over 90% of cases the diagnosis can be made on the morphology of the villous lymphocytes: these small or mediumsized cells have short, thin polar villi and a round nucleus with clumped chromatin and occasionally a prominent nucleolus. The cytoplasm is moderately basophilic and agranular. Circulating plasmacytoid cells are a frequent associated finding. Originally the diagnosis of SLVL required over 30% of circulating lymphocytes to have villous morphology but SLVL can now be diagnosed in patients with lesser numbers of peripheral villous cells if splenic histology and immunophenotyping studies are compatible. 3, 4 Although not diagnostic, the surface marker profile confirms B cell lineage and is helpful to exclude conditions with which SLVL may be confused such as chronic lymphocytic leukaemia (CLL) and hairy cell leukaemia. 5, 6 Villous lymphocytes are typically positive for B cell markers CD19, CD20 and CD22 and negative for CD5 and other T cell and myeloid markers. Lymphocytes in over half the cases react positively with CD11c and DBA44 and negatively with B-ly-7, HC2 and CD25. 3, 5 Analysis of the splenic histology in SLVL has shown that it is identical to splenic marginal-zone lymphoma. 7 These lymphomas have now been included as a provisional entity in the revised European-American classification of lymphoid neoplasms in the category of peripheral B cell neoplasms. 8 Characteristically both the mantle and marginal zones of the splenic white pulp are involved with preservation of the germinal centre. Red pulp may also be heavily infiltrated and tumour cells populate both the peripheral blood and bone marrow. Lymphomas arising in the marginal zone of the spleen tend to have some genetic abnormalities in common including trisomy 3, 9 inactivation of the p53 tumour suppressor gene 10 and BCL1/cyclin D1 gene rearrangements.
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SLVL is an indolent disorder with an 88% 5-year survival, the prognosis being inversely related to the degree of lymphocytosis. 3 Initially splenectomy, which was considered curative, was recommended as the treatment of choice in SLVL. 12 However, as more data have become available concerning the relatively benign natural history of SLVL, an increasingly conservative approach is being adopted, particularly towards symptomless individuals.
Does splenic lymphoma with villous lymphocytes show geographical variation?
Although SLVL has primarily been reported from Europe and north America, it also occurs in Japan, 13 the Middle East 14 and, despite the rarity of chronic lymphoproliferative diseases in Orientals, in China. 15 In these countries descriptions of the disorder do not differ substantially from cases reported from the west. However, we have found that in contrast to the situation in Europe and north America, SLVL in Ghana primarily affects middle-aged women. This gender bias does not appear to be present in other continents though reports are sparse. As in the early studies of SLVL in Europe, massive splenomegaly with Ͼ30% circulating villous lymphocytes have been used as diagnostic criteria for SLVL in Africa, so patients with less advanced disease have not yet been identified. This may be one of the reasons why Ghanaian patients with SLVL invariably also have anaemia and hepatomegaly. Serum paraproteins, without immune paresis, are detected in 10-20%, a lower frequency than in temperate regions. It is likely that the real incidence is higher because the raised background levels of polyclonal immunoglobulins that are consistently present in intensely malarious areas obscure small paraprotein bands on electrophoresis. Although IgM paraproteins are commonly found in SLVL in Europeans, increases in total immunoglobulin levels are not a feature. In west Africa SLVL is often associated with high IgM levels and also with elevated antimalarial antibody titres (Table 1 ). There has been no indication to measure anti-malarial antibodies in SLVL patients from temperate zones but in general, lymphoproliferative disorders tend to be associated with a degree of immune suppression rather than immunoglobulin overproduction. 
Is splenic lymphoma with villous lymphocytes a 'new' disease in Africa?
Because SLVL has only been recognised as a discrete entity in the last decade it is likely to have been categorised previously with disorders such as chronic lymphocytic leukaemia (CLL) or non-Hodgkin's lymphoma with peripheral blood spill-over. For example, in 1966 an SLVL-like disorder, thought to be a variant of CLL, was described in a group of Congolese Bantus who had massive splenomegaly with lymphocytosis and a serum paraprotein. 16 For many years CLL in Africa has been clearly divided into two types. The first affecting elderly men and typified by lymphadenopathy, is identical to CLL in temperate regions. The second variety which is more common in west than east and central Africa, predominantly affects middle-aged women. 17, 18 This latter type -or 'African' CLL -is associated with gross splenic enlargement rather than lymphadenopathy and is clinically and epidemiologically more reminiscent of splenic lymphoma or the non-malignant hyper-reactive malarial splenomegaly than CLL. With the development of sophisticated diagnostic techniques and classification systems it is becoming apparent that 'African' CLL may in fact represent a heterogeneous group of lymphoproliferative disorders. Our studies on west African patients with 'African' CLL have shown that a proportion do indeed have SLVL with at least 30% of circulating lymphocytes being monoclonal B cells with characteristic villous projections. 1 Without access to advanced diagnostic facilities, clinicians in Africa often find it exceedingly difficult to distinguish between lymphoproliferative disorders with splenic involvement and hyper-reactive malarial splenomegaly (HMS, formerly tropical splenomegaly syndrome) because HMS is also associated with splenomegaly and occasionally lymphocytosis. In 1970, the introduction of phytohaemagglutinin stimulation of lymphocytes to differentiate between HMS and malignant lymphoproliferations met with moderate success, a low transformation score implying a lack of response and hence malignant disease. [19] [20] [21] Because some patients with 'African' CLL actually have SLVL and 'African' CLL is often confused with HMS it is highly likely that SLVL may also have been misclassified as HMS.
Tropical 'big spleen' disease -the role of malaria
Persistent massive splenomegaly, measuring over 10 cm from the costal margin, occurs frequently in tropical regions. The classical non-haematological causes are schistosomiasis, leishmaniasis (kala-azar) and portal hypertension and their diagnosis depends on both the clinical picture and a knowledge of the local pattern of diseases. Common haematological causes of massive spleens such as myelofibrosis and chronic granulocytic leukaemia occur in the tropics as in temperate regions. The remaining undiagnosed cases of tropical big spleens were originally grouped together as 'idiopathic tropical splenomegaly' and from this heterogeneous category various lymphoproliferative conditions, both benign and malignant, have been teased out.
An attempt was made to clarify the term 'idiopathic tropical splenomegaly' in 1967 by an international panel which identified a disorder they called 'tropical splenomegaly syndrome'. 22 In 1979, specific major criteria for the diagnosis of tropical splenomegaly syndrome were published; these included raised IgM levels, long-term residence in a malarious area and a response to anti-malarial therapy. 23 Other features such as a positive family history and lymphocytic infiltration of the hepatic sinusoids, were considered to be suggestive of the disorder. Once the syndrome had been clearly defined studies of its pathogenesis could be collated. It became apparent that malaria played a vital role in the development of tropical splenomegaly syndrome: the geographical distribution of the condition corresponded to that of malaria, patients had high anti-malarial antibody titres, the syndrome was rare in those with haemoglobin genotype AS, malaria infection could produce a similar condition in experimental animals and, most compelling of all, malaria prophylaxis could cause regression of the splenomegaly and a reduction in IgM levels. 23 Consequently in 1983 tropical splenomegaly syndrome was renamed hyper-reactive malarial splenomegaly (HMS) to reflect the improved knowledge about its pathological basis. 24 During these studies of HMS, significant geographical differences in prevalence and phenotype were noted. Although HMS predominantly affecting women has been reported from most areas where malaria transmission is intense (the highest prevalence being 80% in the Watut tribe in Papua New Guinea) only in west Africa has it also been associated with a lymphocytosis. 25, 26 Evidence for an association between HMS and SLVL Clinically HMS and SLVL in west Africa are indistinguishable and they have many laboratory features in common. Both are associated with female:male ratio Ͼ1, splenomegaly, lymphocytosis, high IgM levels and raised anti-malarial antibody titres (Table 1 ). All Ghanaian SLVL patients fulfil two of the four major criteria used to diagnose HMS -long-term residence in a malarious area and development of malarial immunity -and many fulfil the third diagnostic criterion by having raised IgM levels. A good response to malaria prophylaxis is the fourth criterion for HMS diagnosis but in tropical practice the majority of patients do not attend follow-up clinics so the effects of anti-malarial drugs cannot be monitored. In those who do receive adequate treatment, significant splenic reduction in HMS only occurs after 6-12 months and therapy must be continued for life to prevent recurrence. Further difficulties arise when trying to use response to treatment to distinguish between HMS and SLVL. Anti-malarial drugs may cause some splenic regression in SLVL patients who are likely to have a degree of immune suppression and to be more susceptible to malaria infections than their normal counterparts. In the past, emphasis has been placed on the need to demon-strate hepatic sinusoidal lymphocytosis in HMS but liver biopsy is only possible in specialist units in Africa and histology services are very limited. Moreover, hepatic sinusoidal lymphocytosis also occurs in chronic infections with EpsteinBarr and hepatitis C viruses, and Felty's syndrome and is therefore a non-specific finding. [27] [28] [29] Despite these diagnostic difficulties it is crucial to make the correct diagnosis as HMS responds well to malaria prophylaxis whereas SLVL, particularly if symptomatic, may require splenectomy. 30 The criteria for HMS were established before SLVL was described and because of the reasons outlined we have found that they are not sufficiently stringent to distinguish between these two conditions. We now employ two further steps to categorically make a diagnosis of HMS rather than SLVL; a sustained reduction in splenic size of at least 40% with anti-malaria drugs (in individuals who attend regularly) and in all patients, a lack of evidence suggesting the presence of monoclonal lymphocytes. We initially assessed lymphocyte clonality by Southern blotting but have latterly employed PCR using primers for the Fr3 and JH regions of the immunoglobulin gene heavy chain. 1, 31 Only since the introduction of these additional investigations have we been able to come to a definitive diagnosis of HMS or SLVL.
Some patients with HMS and no evidence of a clonal population of lymphocytes have large numbers of circulating villous lymphocytes, a phenomenon only previously described in patients with SLVL. 31 This observation, in conjunction with the remarkable epidemiological similarities, identical clinical presentation and the high levels of IgM and anti-malarial antibodies in both disorders has inevitably led us to postulate that these two disorders may be aetiologically related.
The possibility that HMS may precede tumour development has been entertained in the past because of the difficulty experienced in differentiating HMS from neoplastic lymphoproliferative disorders and a clinical suspicion that the high mortality in HMS was linked to the supervention of a lymphoma. 25, 26 With the publication of new consensus guidelines for the classification of non-Hodgkin's lymphomas, 8 and the availability of robust molecular techniques capable of defining lymphocyte clonality in tropical samples, this diagnostic dilemma is being resolved.
Malaria and endemic Burkitt's lymphoma
The obvious example of a role for malaria in the development of lymphoma is in relation to endemic Burkitt's lymphoma. The epidemiological evidence for malaria being a cofactor in this lymphoma is considerable. Endemic Burkitt's lymphoma is only found in areas of high malaria transmission, malaria prophylaxis reduces its incidence, its distribution is similar to that of HMS and malaria infection in laboratory animals enhances the oncogenic potential of tumour viruses. 32 Epstein-Barr virus is likely to be an additional cofactor in the genesis of Burkitt's lymphoma because it is capable of transforming B cells in vivo to produce polyclonal 'tumours', patients have high levels of anti-EBV antibodies and multiple copies of viral genome are present in tumour cells. 32 The classical chromosomal translocation t(8;14) associated with Burkitt's lymphoma juxtaposes the MYC proto-oncogene next to a rearranged immunoglobulin gene locus. 33 Coupled with the effects of other cofactors, this leads to deregulation of the immunoglobulin gene with eventual selection of a single clone which becomes clinically evident as Burkitt's lymphoma. Additionally, EBV transcripts, such as BHRF1 which has homology with BCL-2, may be able to prolong cell survival by interfering with apoptosis, a mechanism already known to operate in follicular lymphomas. 34, 35 How does HMS predispose to the development of splenic lymphoma?
An analogy with endemic Burkitt's lymphoma provides clues to the pathway that may underlie the evolution of HMS into SLVL (Figure 1) . A high rate of B cell proliferation has been demonstrated in HMS resulting in an expanded population of activated B cells. Although malaria is critical in this process an additional role for other infectious agents cannot be excluded. The well-known family and tribal associations of HMS imply a superimposed genetic predisposition. 36, 37 The dysregulated immune response in HMS to repeated malaria infection leads to overproduction of IgM, including abnormal monomeric forms and pure light chains, and the formation of immune complexes. 38 As in Burkitt's lymphoma where the high antibody levels to EBV viral capsid antigen predate the lymphoma, in HMS the high IgM levels precede splenic enlargement and are probably determined during the first decade of life. 39 The presence of grossly elevated anti-malarial antibody titres, autoantibodies including rheumatoid factor, and cryoglobulins in HMS is further evidence of the immunological perturbation. 40 The spleen, and in particular the splenic marginal zone, is the prime presentation site for bloodborne antigens such as the malaria products associated with erythrocytic stages of infection. The constant antigen challenge to which individuals living in areas of intense malaria transmission are exposed, combined with the increased phagocytic drive eventually leads to massive splenic enlargement. At this stage the process is still antigen-driven and reversible if immune stimulation by malaria products is reduced with prophylaxis. Under the influence of continuing malaria challenge and possibly other unknown factors, several clones of lymphocytes emerge which manifest themselves in HMS patients by the presence of oligoclonal, predominantly IgM, paraprotein bands ( Figure 2) . A similar situation occurs in immunosuppressed patients who develop EBV-related lymphomas and even at this stage reversal to a polyclonal state is possible by restoring normal immune function. Infectious agents, notably Helicobacter pylori, are similarly implicated in the development of mucosa-associated (MALT) lymphomas, which respond to appropriate anti-microbial treatment. In animal studies, certain strains of rabbits are able to generate large amounts of monoclonal immunoglobulin in response to immunisation with streptococcal carbohydrate antigens. Weekly immunisation with pneumococcal vaccine for many months can induce a hyper-immune state similar to that seen in chronic parasitic infections like HMS, with the evolution of a predominant monoclonal protein. The lymphocyte clone will regress if the antigen stimulus is withdrawn. This type of immune response to microbial carbohydrates in rabbits appears to be under genetic control. 41 An expanded clone of lymphoid cells is thought to be a pre-requisite for the development of monoclonal gammopathies as these cannot be induced in mice reared in a germ-free environment. 42 Antigen involvement is therefore considered to be crucial in the development of an abnormal clone even though once the mutational event has occurred the cells are no longer amenable to antigenic manipulations.
On the background of malaria-induced lymphocyte proliferation an additional mutational event would favour the out-
Figure 1
Evolution of HMS into lymphoma.
Figure 2
Serum protein electrophoresis showing the gammaglobulin zone towards the bottom of the gel (origin at bottom). A polyclonal gammaglobulin pattern is represented by a smear whereas monoclonal protein production produces a discrete band. Lane 1, normal control from the UK who has lower exposure to infections and therefore less total gammaglobulin than the patients (lanes 2-7) who are all Ghanaian. Lanes 2-5, hyper-reactive malarial splenomegaly (HMS) and splenic lymphoma with villous lymphocytes (SLVL) patients with polyclonal gammaglobulins. Lane 6, HMS patient with several oligoclonal bands in gamma region. Lane 7, SLVL patient with moderate paraprotein band on background of polyclonal increase in gamma globulins. Lane 8, heavy paraprotein in beta region with suppression of total immunoglobulin production.
growth of an autonomous single clone of cells -a lymphoma. Extraneous factors, such as viral protein products, that attenuate the hosts' normal control mechanisms for lymphocyte growth and apoptosis are likely to mediate this process. Such events have been described in SLVL which has been associated with both cyclin D1 overexpression and mutations of the p53 tumour suppression gene. 10, 43 Several infectious organisms are already associated with lymphoproliferative disorders: EBV with Burkitt's lymphoma and Hodgkin's disease, HTLV1 with acute T lymphocytic leukaemia, Helicobacter pylori with mucosa-associated lymphoid tumours and more recently, hepatitis C virus with low-grade non-Hodgkin's lymphomas. 44, 45 According to our hypothesis a lymphoma arising by such a pathway would be expected to:
• have the same geographic and demographic distribution as HMS • show familial predisposition 46 • have similar clinical and morphological features to HMS • have increased IgM levels and anti-malarial antibody titres • produce predominantly IgM paraproteins • arise in the splenic marginal zone, and • show molecular evidence of evolving after exposure to antigen 47 These are all characteristics of SLVL as described in west Africa or elsewhere. Attempts to document this evolutionary process in individual patients in Ghana have been hampered by the chronic and insidious nature of SLVL and the difficulties of long-term observation in the tropics. Studies designed to test our hypothesis in Ghana are underway with particular emphasis on the role of infectious agents such as Epstein-Barr virus, as cofactors. Depite the undoubted challenges of working in developing countries, tropical Africa with its huge burden of infectious diseases, provides a unique environment in which to carry out culturally sensitive research into the mechanisms responsible for the genesis of lymphomas.
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